RRRiccardo Ronco

Riccardo Ronco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Riccardo Ronco has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Blood‐Based Lipid Peroxidation and Ferroptosis‐Related Markers in Friedreich's Ataxia

    by Lidia Sarro, Sara Petrillo, Alessia Mongelli, Riccardo Ronco, Anna Castaldo, Andrea Quatrana, Caterina Torda, Federica Loia, Roberta Telese, Enrico Bertini, et al.

    Background: Friedreich's ataxia (FRDA) is a neurodegenerative disease caused by reduced levels the mitochondrial frataxin protein. Systemic oxidative stress and iron‐dependent lipid peroxidation, commonly associated with ferroptosis, have a critical role in disease pathogenesis. Objectives: We aimed to evaluate longitudinal changes of blood‐based indexes of oxidative stress and ferroptosis‐related molecules in adults and children with FRDA. Methods: We measured plasma levels of 4‐hydroxyl‐2‐nonenals (4‐HNE) and hydroxyeicosatetraenoic acid (15‐HETE), and blood concentration of glutathione (GSH), glutathione disulfide (GSSG), in 62 FRDA patients (48 adults and 14 children) and 63 age matched healthy controls. mRNA levels of major genes targeting the nuclear factor erythroid 2‐related factor 2 (NRF2) were also evaluated. Peripheral concentrations of lipid peroxidation markers and ferroptosis‐related molecules were correlated with age, disease duration, and severity of ataxia signs. Clinical and biochemical evaluations were performed at baseline and at 1‐year follow‐up. Results: FRDA patients had significantly increased levels of 4‐HNE and GSSG and decreased levels of GSH, compared to controls. Children with FRDA had lower levels of glutathione peroxidase 4 ( GPX4 ) mRNA than adult patients. At 1‐year follow up, plasma 4‐HNE levels remained stable, and blood GPX4 mRNA increased only in adult patient cohort. GPX4 correlated with age, disease duration, and clinical scores. Conclusions: We provide preliminary evidence of defective GPX4 expression in the early phase of the disease. Our data suggest that GPX4 may represent a biomarker for disease progression and a possible candidate target for therapeutic strategies. © 2026 International Parkinson and Movement Disorder Society.

  • Open Access

    Mutations in alpha‐B‐crystallin cause autosomal dominant axonal Charcot–Marie–Tooth disease with congenital cataracts

    by Andrea Cortese, Riccardo Currò, Riccardo Ronco, Julian Blake, Alex M. Rossor, Enrico Bugiardini, Matilde Laurà, Tom Warner, Tarek Yousry, Roy Poh, et al.

    Background and purpose: Mutations in the alpha‐B‐crystallin (CRYAB) gene have initially been associated with myofibrillar myopathy, dilated cardiomyopathy and cataracts. For the first time, peripheral neuropathy is reported here as a novel phenotype associated with CRYAB.Methods: Whole‐exome sequencing was performed in two unrelated families with genetically unsolved axonal Charcot–Marie–Tooth disease (CMT2), assessing clinical, neurophysiological and radiological features.Results: The pathogenic CRYAB variant c.358A>G;p.Arg120Gly was segregated in all affected patients from two unrelated families. The disease presented as late onset CMT2 (onset over 40 years) with distal sensory and motor impairment and congenital cataracts. Muscle involvement was probably associated in cases showing mild axial and diaphragmatic weakness. In all cases, nerve conduction studies demonstrated the presence of an axonal sensorimotor neuropathy along with chronic neurogenic changes on needle examination.Discussion: In cases with late onset autosomal dominant CMT2 and congenital cataracts, it is recommended that CRYAB is considered for genetic testing. The identification of CRYAB mutations causing CMT2 further supports a continuous spectrum of expressivity, from myopathic to neuropathic and mixed forms, of a growing number of genes involved in protein degradation and chaperone‐assisted autophagy.